Trials / Completed
CompletedNCT02452814
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
Conditions
Timeline
- Start date
- 2014-05-07
- Primary completion
- 2017-05-03
- Completion
- 2017-05-03
- First posted
- 2015-05-25
- Last updated
- 2018-02-06
Locations
3 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT02452814. Inclusion in this directory is not an endorsement.